Currently Viewing:
Newsroom
Currently Reading
FDA Approves Rituxan Hycela for Treating Certain Blood Cancers
June 24, 2017 – Alison Rodriguez
FDA Approves of Darzalex Combination for Multiple Myeloma
June 23, 2017 – Alison Rodriguez
Family History, Mutation Location Increase Risks of Breast, Ovarian Cancers
June 23, 2017 – Alison Rodriguez
Dr Yousuf Zafar of Duke Cancer Institute Joins The Samfund's Advisory Council
June 22, 2017 – AJMC Staff
FDA Approves Baxdela for Skin Infections
June 22, 2017 – Alison Rodriguez
What We're Reading: ACA Insurers File; Missouri Sues Opioid Manufacturers; Mylan's EpiPen Deals
June 22, 2017 – AJMC Staff
Mutation Burden and PD-L1 Expression Influence Response to Nivolumab in NSCLC
June 22, 2017 – Christina Mattina
Developing a Creative Strategy to Present the Value of Oncology Drugs
June 22, 2017 – Surabhi Dangi-Garimella, PhD
Research Warns Patients of Drug-Drug and Herb-Drug Interactions
June 21, 2017 – Christina Mattina

FDA Approves Rituxan Hycela for Treating Certain Blood Cancers

Alison Rodriguez
The FDA has approved Genentech’s Rituxan Hycela for subcutaneous injection for the treatment of certain blood cancers. Rituxan Hycela has similar outcomes as Rituxan, but can be delivered in 5 to 7 minutes compared with 1.5 hours for Rituxan.
The FDA has approved Genentech’s Rituxan Hycela for subcutaneous injection for the treatment of certain blood cancers. The new treatment is a combination of the monoclonal antibody in intravenous Rituxan (rituximab) and hyaluronidase human, an enzyme that assists in delivering rituximab beneath the skin.

Rituxan Hycela is approved for the treatment of previously untreated and relapsed or refractory follicular lymphoma, previously untreated diffuse large B-cell lymphoma, and previously treated or untreated chronic lymphocytic leukemia. The FDA approved of the drug because of results from multiple clinical studies that revealed non-inferior levels of rituximab in the blood with subcutaneous injections of Rituxan Hycela.

The efficacy outcomes of Rituxan Hycela often mirrored those of Rituxan. Since Rituxan Hycela requires less time to administer in a clinic, 77% of patients prefer it over Rituxan, according to one of the studies submitted to the FDA. Treatment time for Rituxan Hycela takes 5 to 7 minutes compared to the 1.5 hours or more it takes to administer Rituxan. However, Rituxan will continue to be available for treatment use, as patients may only receive Rituxan Hycela following at least one full dose of intravenous Rituxan.

“With today’s approval of Rituxan Hycela, people with 3 of the most common blood cancers now have a new treatment option which provides efficacy comparable with intravenous Rituxan and can be delivered under the skin in minutes instead of hours through IV infusion,” Sandra Horning, MD, the chief medical officer and head of Global Product Development at Genentech, said in a statement.

Rituxan Hycela also had similar adverse reactions as Rituxan. Among the 3 types of blood cancer that Rituxan Hycela treats, the most common adverse reactions include infection and nausea.

“People who benefit from Rituxan may receive years of repeated treatments for their blood cancer, so an option that reduces the administration time can be important,” concluded Horning.

 
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up